Venous Thromboembolism and Gut Dysbiosis: Mechanistic Links Between Endotoxemia, Microbial Metabolites, and Thromboinflammation
Open Access
Abstract
Background: Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, is increasingly recognized as a thromboinflammatory disorder involving coagulation, innate immunity, endothelial dysfunction, and vascular homeostasis. Emerging evidence suggests that gut microbiome-related inflammatory and metabolic signals may influence pathways potentially relevant to VTE through intestinal barrier dysfunction, microbial translocation, and microbiome-derived metabolites. This review critically examines the direct and indirect evidence relating gut dysbiosis to mechanisms potentially relevant to venous thrombogenesis. Methods: A structured literature search of PubMed, Scopus, and Web of Science was conducted from database inception to February 2026. Observational, translational, experimental, preclinical, and selected genetic studies were narratively synthesized across heterogeneous evidence types. Results: Available evidence suggests that intestinal barrier dysfunction and microbial translocation may increase systemic exposure to lipopolysaccharide and other microbial products, potentially contributing to inflammatory signaling and procoagulant responses. Proposed downstream effects include tissue factor (TF) activation, platelet reactivity, neutrophil extracellular traps (NETs) formation, complement signaling, endothelial perturbation, and impaired balance of anticoagulant and fibrinolytic pathways. Microbiome-derived metabolites, including trimethylamine N-oxide (TMAO), phenylacetylglutamine (PAGln), bile acids, and short-chain fatty acids (SCFAs), have been linked, mainly in experimental or non-VTE settings, to thrombosis-related biology. However, most evidence remains indirect, associative, or experimental, whereas direct human VTE-specific evidence is limited and heterogeneous. Conclusions: The gut microbiome–VTE axis is biologically plausible and supported mainly by mechanistic and indirect evidence, but current data are insufficient to support strong causal conclusions. Further longitudinal, well-phenotyped, mechanistically informed studies are needed to determine whether microbiome-related pathways have measurable clinical relevance in human VTE.Keywords
This publication has 235 references indexed in Scilit:
- Association Between Use of Pharmacokinetic‐Interacting Drugs and Effectiveness and Safety of Direct Acting Oral Anticoagulants: Nested Case‐Control StudyClinical Pharmacology & Therapeutics, 2021
- Visceral fat‐specific regulation of plasminogen activator inhibitor‐1 in aged septic miceJournal of Cellular Physiology, 2021
- TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signalingCellular and Molecular Life Sciences, 2020
- Intestinal Efflux Transporters P-gp and BCRP Are Not Clinically Relevant in Apixaban DispositionPharmaceutical Research, 2020
- Venous thromboembolism 2011–2018 in Stockholm: a demographic studyJournal of Thrombosis and Thrombolysis, 2019
- Pharmacomicrobiomics: The Holy Grail to Variability in Drug Response?Clinical Pharmacology & Therapeutics, 2019
- Venous thromboembolism: thrombosis, inflammation, and immunothrombosis for cliniciansJournal of Thrombosis and Thrombolysis, 2017
- The epidemiology of venous thromboembolismJournal of Thrombosis and Thrombolysis, 2016
- Protein C anticoagulant system—anti-inflammatory effectsSeminars in Immunopathology, 2011
- An automated database case definition for serious bleeding related to oral anticoagulant usePharmacoepidemiology and Drug Safety, 2011